Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.» Read More
Mobile payments may be all the rage, but a Canadian based start-up is betting that some consumers will want to wear their payment source.
There is no shortage of data driven dating services, but a start-up called SingldOut is using a much more personal data set to help people find love.
The White House has managed to move forward from Veteran Affairs health care scandal, among other events, reports NBC News.
China's healthcare sector is growing at more than double the pace of the overall economy, according to the CEO of Johnson & Johnson.
The Obama administration says less than 10 million people are likely to sign up for Obamacare by 2015, much less than 13 million projected earlier.
NASH, or nonalcoholic steatohepatitis, is a liver disease that may affect as much as 12 percent of the U.S. population, Genfit's Dean Hum said.
Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful.
Did Obamacare have an inadvertent poison pill in there all along?
Arrowhead Research Chief Executive Chris Anzalone contends the company's hepatitis B therapy, ARC-520, has potential.
Craig Spencer, the New York City doctor who contracted Ebola, is being released from Bellevue Hospital Center, the NYT reports.
Apple's online store lists a lot of fitness-related products, but don't look for Fitbit.
In response to President Obama's proposal on broadband regulations, Ted Cruz tweeted on Monday that net neutrality is like Obamacare for the Internet.
The Supreme Court made the "right decision" to hear claims that financial aid to HealthCare.gov customers is illegal, a mastermind of the theory says.
Robots are joining doctors and scientists in combating the deadly Ebola outbreak.
Researchers, companies and Wall Street are gathering to gain a sense of bringing potentially multibillion dollar drugs to market.
Many customers shopping for Obamacare's most popular plans will see only modest increases—or even price cuts—on many of the cheapest plans.
To fast-track autism research, Google and scientists are using data analytics to find its roots and possible cures.
Weeks after Facebook's CEO gave $25 million to fight Ebola in Africa, his company is rolling out three initiatives to raise awareness and more money.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
Pascal Soriot, chief executive of AstraZeneca, said the U.S. had nearly removed the effect of tax inversion deals like Pfizer's bid for his company.
Get the best of CNBC in your inbox